Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bayer Schering IND Filing Triggers Milestones | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Bayer Schering IND Filing Triggers Milestones

Bayer Schering Pharma AG has filed to initiate a Phase I trial of MN-IC, an antibody-drug conjugate (ADC) for oncology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bayer Schering Pharma AG has filed to initiate a Phase I trial of MN-IC, an antibody-drug conjugate (ADC) for oncology. The move triggers milestone payments to MorphoSys AG and Seattle Genetics. Terms of the payments were not disclosed, but a MorphoSys statement referred to it as “significant.”

Bayer Schering licensed Seattle Genetics’ ADC technology with antibodies against target molecule MN, also known as carbonic anhydrase, a tumor-associated antigen expressed in many tumor types under hypoxic conditions. The antibody component of the treatment is derived from MorphoSys’ HuCal technology.

Read our profile of Bayer Schering in this year’s Top Companies Report!

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters